DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qwf4qh/rigilike) has announced the addition of the "RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013" report to their offering.
Extra value: One year of free online updates included with this product
Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs).
There are today 53 companies plus partners developing 32 RIG-I-like receptor signaling pathway targeting drugs in 106 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Rig-I-Like Receptor Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 60 different targets. These targets are further categorized on in the software application by 17 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
For more information visit http://www.researchandmarkets.com/research/qwf4qh/rigilike